Literature DB >> 26693820

Resistant Hypertension: Mineralocorticoid Receptor Antagonist or Renal Denervation?

Robert M Carey1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26693820      PMCID： PMC4713293          DOI： 10.1161/HYPERTENSIONAHA.115.06616

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  11 in total

1.  Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial.

Authors:  Michel Azizi; Marc Sapoval; Philippe Gosse; Matthieu Monge; Guillaume Bobrie; Pascal Delsart; Marco Midulla; Claire Mounier-Véhier; Pierre-Yves Courand; Pierre Lantelme; Thierry Denolle; Caroline Dourmap-Collas; Hervé Trillaud; Helena Pereira; Pierre-François Plouin; Gilles Chatellier
Journal:  Lancet       Date:  2015-01-26       Impact factor: 79.321

Review 2.  Resistant hypertension--its identification and epidemiology.

Authors:  Pantelis A Sarafidis; Panagiotis Georgianos; George L Bakris
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

3.  Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study.

Authors:  Ján Rosa; Petr Widimský; Petr Waldauf; Lukáš Lambert; Tomáš Zelinka; Miloš Táborský; Marian Branny; Petr Toušek; Ondřej Petrák; Karol Čurila; František Bednář; Robert Holaj; Branislav Štrauch; Jan Václavík; Igor Nykl; Zuzana Krátká; Eva Kociánová; Otakar Jiravský; Gabriela Rappová; Tomáš Indra; Jiří Widimský
Journal:  Hypertension       Date:  2015-12-22       Impact factor: 10.190

4.  Prevalence of resistant hypertension in the United States, 2003-2008.

Authors:  Stephen D Persell
Journal:  Hypertension       Date:  2011-04-18       Impact factor: 10.190

5.  Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure.

Authors:  Tanja Dudenbostel; Maria C Acelajado; Roberto Pisoni; Peng Li; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2015-05-18       Impact factor: 10.190

Review 6.  Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013.

Authors:  William B White; J Rick Turner; Domenic A Sica; John D Bisognano; David A Calhoun; Raymond R Townsend; Herbert D Aronow; Deepak L Bhatt; George L Bakris
Journal:  J Am Soc Hypertens       Date:  2014-07-15

7.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

8.  A controlled trial of renal denervation for resistant hypertension.

Authors:  Deepak L Bhatt; David E Kandzari; William W O'Neill; Ralph D'Agostino; John M Flack; Barry T Katzen; Martin B Leon; Minglei Liu; Laura Mauri; Manuela Negoita; Sidney A Cohen; Suzanne Oparil; Krishna Rocha-Singh; Raymond R Townsend; George L Bakris
Journal:  N Engl J Med       Date:  2014-03-29       Impact factor: 91.245

9.  Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension.

Authors:  John J Sim; Simran K Bhandari; Jiaxiao Shi; Kristi Reynolds; David A Calhoun; Kamyar Kalantar-Zadeh; Steven J Jacobsen
Journal:  Kidney Int       Date:  2015-05-06       Impact factor: 10.612

10.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321
View more
  2 in total

Review 1.  Should All Patients with Resistant Hypertension Receive Spironolactone?

Authors:  Ján Rosa; Tomáš Zelinka; Ondřej Petrák; Branislav Štrauch; Robert Holaj; Jiří Widimský
Journal:  Curr Hypertens Rep       Date:  2016-11       Impact factor: 5.369

Review 2.  The Na+/H+ Exchanger 3 in the Intestines and the Proximal Tubule of the Kidney: Localization, Physiological Function, and Key Roles in Angiotensin II-Induced Hypertension.

Authors:  Sarah M Nwia; Xiao Chun Li; Ana Paula de Oliveira Leite; Rumana Hassan; Jia Long Zhuo
Journal:  Front Physiol       Date:  2022-04-19       Impact factor: 4.755
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.